Spesolimab in Pyoderma Gangrenosum

Key facts

Sponsor

Icahn School of Medicine at Mount Sinai

Principal Investigator

Saakshi Khattri, MD

Icahn School of Medicine at Mount Sinai

Intervention

Spesolimab(drug)

Enrollment

5 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2025

Study locations (1)

• Icahn School of Medicine at Mount Sinai, New York, New York, United States

Collaborators

Boehringer Ingelheim

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06624670
  A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT06563323
  Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
  Oregon Health and Science University

See all trials for Classic pyoderma gangrenosum →